3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Thyroid Neoplasms
17
Squamous Cell Carcinoma of Head and Neck
8
Thyroid Carcinoma, Anaplastic
5
Thyroid Cancer, Papillary
3
Endometrial Neoplasms
3
Adenocarcinoma, Follicular
3
Triple Negative Breast Neoplasms
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid cancer, medullary
1
Thyroid cancer, Hurthle cell
1
Thyroid Diseases
1
Thyroid Cancer Metastatic
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Locally Advanced Thyroid Gland Carcinoma
1
Head and Neck Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Differentiated Thyroid Cancer (DTC)
1
Interventions
Trastuzumab
3
Docetaxel
3
Cisplatin
3
pembrolizumab
2
Nivolumab
2
Gemcitabine
2
Capecitabine
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
trastuzumab deruxtecan
1
tipifarnib
1
seribantumab
1
sargramostim
1
pertuzumab
1
lenvatinib
1
entinostat
1
Thalidomide
1
Taxes
1
Specimen Handling
1
Platinum
1
Paclitaxel
1
Oxaliplatin
1
Magnetic Resonance Spectroscopy
1
Irinotecan
1
Ipilimumab
1
Interleukin-12 Subunit p35
1
Interleukin-12
1
Immunohistochemistry
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Fluorouracil
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gallbladder Neoplasms
×
lenvatinib
×
Head & Neck
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled